

## Tepezza<sup>®</sup> (teprotumumab-trbw) – Updated indication

- On April 14, 2023, [Horizon Therapeutics announced](#) the FDA approval of [Tepezza \(teprotumumab-trbw\)](#), for the treatment of thyroid eye disease **regardless of thyroid eye disease activity or duration**.
  - Tepezza was previously approved for treatment of thyroid eye disease.
- The label update follows positive topline results from a randomized, double-masked, placebo-controlled Phase 4 clinical trial that were announced last week, which demonstrated that patients with an initial diagnosis of thyroid eye disease between two to 10 years and with low disease activity, achieved a statistically significant reduction in proptosis from baseline at Week 24 after receiving Tepezza compared to those receiving placebo.
- The recommended dose of Tepezza is an intravenous (IV) infusion of 10 mg/kg for the initial dose followed by an IV infusion of 20 mg/kg every three weeks for 7 additional infusions.